AIM ImmunoTech Inc. (AIM) Key Metrics
AIM valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $6.7M
- Enterprise value
- $2.2M
- P/E (TTM)
- —
- Forward P/E
- 2.0
- PEG ratio
- 0.71
- Price / sales
- 70.6
- Price / book
- 1.1
- EV / EBITDA
- 0.5
- Dividend yield
- —
- Beta
- 1.27
AIM key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAIM returns How much profit the business earns on the capital it uses.
Return on assets−70.2 pts
−194.0%
2025 · hover or tap a bar for each year
20162025
Asset turnover+0.7%
0.01
2025 · hover or tap a bar for each year
20162025
AIM financial health Debt, liquidity and how easily interest is covered.
Net debt+$4.9M
$3.9M
2025 · hover or tap a bar for each year
20162025
Current ratio+20.9%
0.53
2025 · hover or tap a bar for each year
20162025
Interest coverage
-13.0
2025 · hover or tap a bar for each year
20162025
Debt / assets+147.8%
0.85
2025 · hover or tap a bar for each year
20162025
AIM efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding
29 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−71,181 days
4,327 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle
-4,298 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+419.0 pts
429.5%
2025 · hover or tap a bar for each year
20162025
AIM returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AIM debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AIM key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $1.13 | $19.78 | $43.95 | $31.16 | $91.91 | $178.82 | $54.35 | $795.50 | $1,521.01 | $3,032.20 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −118.9% | −40.8% | −32.4% | −38.8% | −104.0% | −141.4% | −68.3% | −41.8% |
| Return on invested capital (ROIC) | — | — | — | −226.9% | −89.3% | −68.2% | −99.4% | −102.6% | −99.9% | −103.4% |
| Return on assets (ROA) | −194.0% | −123.8% | −96.8% | −39.6% | −22.7% | −21.9% | −55.2% | −70.0% | −49.9% | −36.0% |
| Return on tangible assets | −338.7% | −288.0% | −169.7% | −50.4% | −34.3% | −13.1% | −49.3% | −75.9% | −61.9% | −41.7% |
| Financial health | ||||||||||
| Total debt | $4.9M | $2.9M | $718,000 | $837,000 | $149,000 | $2.3M | $6.4M | $5.9M | $1.8M | — |
| Cash & short-term investments | $993,000 | $4.0M | $13.1M | $34.2M | $48.3M | $39.0M | $8.8M | $1.8M | $2.1M | $5.9M |
| Net debt | $3.9M | −$1.0M | −$12.4M | −$33.4M | −$48.1M | −$36.7M | −$2.4M | $4.1M | −$272,000 | −$5.9M |
| Debt / equity | — | — | 0.07 | 0.02 | 0.00 | 0.04 | 0.49 | 1.15 | 0.21 | — |
| Debt / assets | 0.85 | 0.34 | 0.04 | 0.02 | 0.00 | 0.02 | 0.32 | 0.43 | 0.13 | — |
| Current ratio | 0.53 | 0.44 | 1.68 | 26.69 | 74.61 | 36.58 | 9.27 | 0.72 | 1.29 | 2.85 |
| Quick ratio | 0.53 | 0.44 | 1.72 | 26.69 | 74.61 | 36.58 | 9.27 | 0.72 | 1.29 | 2.85 |
| Interest coverage | -13.0 | -33.8 | — | -41.7 | -281.2 | -22.5 | -29.1 | -22.9 | -82.1 | -107.0 |
| Working capital | −$2.9M | −$5.4M | $5.9M | $35.0M | $49.5M | $39.2M | $9.3M | −$1.5M | $798,000 | $4.5M |
| Invested capital | −$5.9M | −$2.4M | −$2.1M | $5.1M | $8.8M | $24.6M | $10.5M | $9.3M | $8.4M | $9.6M |
| Tangible asset value | −$11.4M | −$3.9M | $7.9M | $36.5M | $54.9M | $59.8M | $11.8M | $4.3M | $7.8M | $14.6M |
| Net current asset value | −$12.3M | −$5.8M | $5.4M | $34.3M | $49.4M | −$9.4M | $3.1M | −$4.9M | −$2.0M | $3.6M |
| Capital allocation | ||||||||||
| Share buybacks (net) | $0 | $0 | $0 | $0 | — | — | — | — | — | — |
| Capex / revenue | 429.5% | 10.6% | 289.6% | 192.2% | 30.4% | 365.0% | 260.7% | 34.6% | 15.8% | 493.5% |
| Capex / depreciation | 1.80 | 0.07 | 2.46 | 1.06 | 0.05 | 0.81 | 0.46 | 0.14 | 0.07 | 0.39 |
| Stock-based compensation / revenue | 68.2% | 403.5% | 120.3% | 676.6% | 1,161.5% | 635.6% | 609.3% | 253.1% | 130.7% | 445.7% |
| R&D / revenue | 4,459.1% | 3,645.3% | 5,408.4% | 4,957.4% | 5,683.0% | 3,509.2% | 3,322.1% | 1,301.9% | 937.8% | 5,551.1% |
| SG&A / revenue | 8,750.0% | 8,067.1% | 10,772.3% | 9,512.8% | 6,423.7% | 5,309.2% | 5,027.9% | 1,689.6% | 1,503.9% | 8,348.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 29.0 | — | 2,583.9 | 4,293.3 | 3,737.9 | 2,176.6 | 2,495.0 | 556.0 | 20.0 | — |
| Days of inventory on hand | — | — | -2,624.5 | — | — | — | 0.0 | 0.0 | — | — |
| Days payables outstanding | 4,326.5 | 75,507.9 | 29,634.5 | -247.5 | 124.7 | 193.6 | 235.4 | 293.4 | 251.1 | 345.9 |
| Cash conversion cycle (days) | -4,297.5 | — | -29,675.1 | 4,540.8 | 3,613.1 | 1,983.0 | 2,259.6 | 262.6 | -231.1 | — |
| Receivables turnover | 12.57 | — | 0.14 | 0.09 | 0.10 | 0.17 | 0.15 | 0.66 | 18.21 | — |
| Payables turnover | 0.08 | 0.00 | 0.01 | −1.47 | 2.93 | 1.89 | 1.55 | 1.24 | 1.45 | 1.06 |
| Inventory turnover | — | — | — | — | — | — | 893,000.00 | 884,000.00 | — | — |
| Asset turnover | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 |
| Average receivables | $7,000 | — | $1.4M | $1.7M | $1.4M | $972,000 | $957,000 | $559,000 | $24,000 | — |
| Average payables | $4.0M | $6.4M | $3.4M | $287,500 | $290,500 | $427,500 | $576,000 | $710,500 | $814,000 | $1.1M |
| Average inventory | — | — | −$302,000 | — | — | — | $1 | $1 | — | — |
| Intangibles / total assets | 28.7% | 30.1% | 11.9% | 4.8% | 3.4% | 1.3% | 5.7% | 6.6% | 6.0% | 4.6% |
Computed from AIM's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AIM valuation and financial ratios
It ended the year with $4.9 million of debt and $1.0 million in cash and short-term investments, net debt of $3.9 million.
See the AIM income statement, the AIM chart for price history, or the AIM stock overview for the latest quote and news.
AIM key metrics FAQ
How much debt does AIM ImmunoTech have?
AIM ImmunoTech had total debt of $4.9 million at the end of fiscal 2025.
What is AIM ImmunoTech's current ratio?
AIM ImmunoTech's current ratio was 0.53 at the end of fiscal 2025: current assets were 0.53 times current liabilities.